Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti‐CD20 therapy: the B‐cell roadblock hypothesis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Immunological Reviews

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-065X.2008.00627.xPMID 18613836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

  2008cited by this paper
• Macrophage Migration Inhibitory Factor Induces B Cell Survival by Activation of a CD74-CD44 Receptor Complex*

  2008cited by this paper
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Interleukin-21: basic biology and implications for cancer and autoimmunity.

  2008cited by this paper
• Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

  2007cited by this paper
• Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.

  2007cited by this paper
• Cells of the synovium in rheumatoid arthritis. Dendritic cells

  2007cited by this paper
• Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice

  2007cited by this paper
• Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.

  2007cited by this paper
• Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

  2007influential reference
• B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

  2007cited by this paper
• Cells of the synovium in rheumatoid arthritis. Osteoclasts

  2007cited by this paper
• Essential Role of IL-21 in B Cell Activation, Expansion, and Plasma Cell Generation during CD4+ T Cell-B Cell Collaboration1

  2007cited by this paper
• Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

  2007cited by this paper
• Macrophages and their products in rheumatoid arthritis

  2007cited by this paper
• Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response

  2007cited by this paper
• Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.

  2007cited by this paper
• Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis.

  2007cited by this paper
• Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis.

  2007cited by this paper
• T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue.

  2007cited by this paper
• Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

  2007influential reference
• Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers.

  2007cited by this paper
• Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.

  2007cited by this paper
• Depletion of B Cells in Murine Lupus: Efficacy and Resistance1

  2007cited by this paper
• CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans

  2006cited by this paper
• Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

  2006cited by this paper
• Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.

  2006cited by this paper
• Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

  2006cited by this paper
• B cell immunobiology in disease: evolving concepts from the clinic.

  2006cited by this paper
• Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.

  2006cited by this paper
• MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis

  2006influential reference
• Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

  2006cited by this paper
• The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper
• Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1

  2005cited by this paper
• Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis 1

  2005cited by this paper
• Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases.

  2005cited by this paper
• Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis

  2005cited by this paper
• Fibroblast-Like Synoviocytes of Mesenchymal Origin Express Functional B Cell-Activating Factor of the TNF Family in Response to Proinflammatory Cytokines1

  2005cited by this paper
• Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis

  2005cited by this paper
• Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody

  2005cited by this paper
• Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

  2004influential reference
• Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients.

  2004cited by this paper
• Immunohistochemical analysis of proliferating and antigen-presenting cells in rheumatoid synovial tissue

  2004cited by this paper
• Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?1

  2004cited by this paper
• Lymphoid neogenesis in rheumatoid synovitis

  2003cited by this paper
• Plasma Cell Survival Is Mediated by Synergistic Effects of Cytokines and Adhesion-Dependent Signals1

  2003cited by this paper
• Prevention of Arthritis by Interleukin 10–producing B Cells

  2003cited by this paper
• G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS

  2003cited by this paper
• Ectopic Germinal Center Formation in Rheumatoid Synovitis

  2003cited by this paper
• Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.

  2003cited by this paper
• Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

  2003cited by this paper
• Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

  2003cited by this paper
• Morphological and molecular pathology of the B cell response in synovitis of rheumatoid arthritis

  2002cited by this paper
• Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism.

  2001influential reference
• T Cell Activation in Rheumatoid Synovium Is B Cell Dependent1

  2001cited by this paper
• Lymphoid Chemokine B Cell-Attracting Chemokine-1 (CXCL13) Is Expressed in Germinal Center of Ectopic Lymphoid Follicles Within the Synovium of Chronic Arthritis Patients1

  2001cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• Lymphoid Neogenesis in Rheumatoid Synovitis1

  2001cited by this paper
• Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

  2001cited by this paper
• Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

  2000cited by this paper
• Histopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis.

  2000cited by this paper
• IgVH genes from different anatomical regions, with different histopathological patterns, of a rheumatoid arthritis patient suggest cyclic re-entry of mature synovial B-cells in the hypermutation process

  2000cited by this paper
• Immunohistological analysis of synovial tissue for differential diagnosis in early arthritis.

  1999cited by this paper
• The B lymphocyte in rheumatoid arthritis: recirculation of B lymphocytes between different joints and blood.

  1999cited by this paper
• Use of differential subtraction method to identify genes that characterize the phenotype of cultured rheumatoid arthritis synoviocytes.

  1998cited by this paper
• A novel monospecific IgG2/lambda-autoantibody with specificity for a mitochondrial antigen: evidence for an antigen-driven pathogenetic B-cell response in rheumatoid synovial tissue, induced by tissue alteration.

  1998cited by this paper
• Analysis of VH gene rearrangements from synovial B cells of patients with rheumatoid arthritis reveals infiltration of the synovial membrane by memory B cells

  1997cited by this paper
• Clonal analysis of immunoglobulin mRNA in rheumatoid arthritis synovium: Characterization of expanded IgG3 populations

  1997cited by this paper
• B-cell activation and development within chronically inflamed synovium in rheumatoid and reactive arthritis.

  1997cited by this paper
• Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis.

  1996cited by this paper
• The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium.

  1995cited by this paper
• Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry.

  1990cited by this paper
• The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. II. Effects on immune and inflammatory indices in peripheral blood.

  1988cited by this paper
• The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. III. Effects on immune and inflammatory indices in synovial fluid.

  1988cited by this paper
• The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I. Clinical effects.

  1988cited by this paper
• Methylprednisolone infusion therapy in rheumatoid arthritis patients. The effect on synovial fluid lymphocyte subsets and inflammatory indices.

  1986cited by this paper
• Immunohistologic characterization of synovial membrane lymphocytes in rheumatoid arthritis.

  1984cited by this paper
• An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies.

  1982cited by this paper
• The immunopathology of joint inflammation in rheumatoid arthritis.

  1973cited by this paper

• Anti-CD20 monoclonal antibodies for idiopathic nephrotic syndrome: Advances, challenges, and future directions

  2025cites this paper
• Rheumatoid arthritis unmasked: the power of B cell depletion therapy

  2025cites this paper
• The role of anti-citrullinated protein antibody in pathogenesis of RA

  2024cites this paper
• Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials

  2023cites this paper
• Synovial Macrophages: Past Life, Current Situation, and Application in Inflammatory Arthritis

  2022cites this paper
• Rituximab Therapy for Primary Sjögren’s Syndrome

  2021cites this paper
• Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.

  2020cites this paper
• Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire

  2019cites this paper
• Rituximab levels are associated with the B cell homeostasis but not with the clinical response in patients with rheumatoid arthritis

  2019cites this paper
• CD3+CD20+ T cells and their roles in human diseases.

  2019cites this paper
• Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin

  2018cites this paper
• Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.

  2018cites this paper
• The diagnosis and clinical management of the neuropsychiatric manifestations of lupus.

  2016cites this paper
• Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE

  2016cites this paper
• The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

  2015cites this paper
• Влияние терапии генно-инженерными биологическими препаратами на субпопуляции В-лимфоцитов при ревматических заболеваниях: новые данные

  2015cites this paper
• Inhibition of the Interleukin-6 Signaling Pathway: A Strategy to Induce Immune Tolerance

  2014cites this paper
• Successful therapy of rheumatoid pleural effusion with rituximab - a case report

  2014cites this paper
• Apoptotic B cells: their interactions with macrophages and modulation by rituximab

  2014cites this paper
• Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis

  2014cites this paper
• Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.

  2014cites this paper
• Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell Responses

  2014cites this paper
• Monoclonal antibody treatments for rheumatoid arthritis

  2013cites this paper
• B Cells in Inflamed Lymph Nodes: A Link between Inflammation and Autoimmunity

  2012cites this paper
• Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunity.

  2012cites this paper
• Saposin C Coupled Lipid Nanovesicles Specifically Target Arthritic Mouse Joints for Optical Imaging of Disease Severity

  2012cites this paper
• Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.

  2011cites this paper
• B Cell Depletion Reduces the Number of Autoreactive T Helper Cells and Prevents Glucose-6-Phosphate Isomerase-Induced Arthritis

  2011cites this paper
• Recombinant proteins in rheumatology - recent advances.

  2011cites this paper
• In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.

  2011cites this paper
• B cell therapies for rheumatoid arthritis: beyond B cell depletion.

  2010cites this paper
• Serum BAFF strongly correlates with PsA activity in male patients only--is there a role for sex hormones?

  2010cites this paper
• Current aspects of anti-CD20 therapy in rheumatoid arthritis.

  2010cites this paper
• Down regulation of Fc and complement receptors on B cells in rheumatoid arthritis.

  2010cites this paper
• Response to Rituximab and Timeframe to Relapse in Rheumatoid Arthritis Patients

  2010cites this paper
• MS4a4B, a CD20 Homologue in T Cells, Inhibits T Cell Propagation by Modulation of Cell Cycle

  2010cites this paper
• B‐cell targeted therapies in human autoimmune diseases: an updated perspective

  2010cites this paper
• Rituximab in autoimmune hematologic diseases: not just a matter of B cells.

  2010cites this paper
• The role of B cells in regulating the magnitude of immune response

  2010cites this paper
• Fundamentals of Inflammation

  2010cites this paper
• Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis

  2009cites this paper
• Antibodies for therapeutic uses and the evolution of biotechniques.

  2009cites this paper
• Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.

  2009cites this paper
• Translationale Aspekte zur Rolle von B-Zellen bei Autoimmunerkrankungen

  2009cites this paper
• B-cell-directed therapies for autoimmune disease

  2009cites this paper
• Depletion of functionally active CD20+ T cells by rituximab treatment.

  2009cites this paper
• Siglecs as targets for therapy in immune-cell-mediated disease.

  2009cites this paper
• Superiority of ear skin for DNA immunization in mouse tumor models

  2008cites this paper
• Therapeutic advances in rheumatology with the use of recombinant proteins

  2008cites this paper
• A golden era of opportunity in immunotherapy discovery and development

  2008cites this paper